Artemether
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Artemether
Description:
Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria[1].Product Name Alternative:
Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224UNSPSC:
12352005Hazard Statement:
H302Target:
ParasiteType:
Natural ProductsRelated Pathways:
Anti-infectionApplications:
COVID-19-immunoregulationField of Research:
Cancer; Infection; Inflammation/ImmunologyAssay Protocol:
https://www.medchemexpress.com/artemether.htmlPurity:
99.20Solubility:
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mLSmiles:
C[C@H]1[C@@H](OC)O[C@@]2([H])[C@]34[C@@]([C@H](C)CC[C@]41[H])([H])CC[C@@](O2)(C)OO3Molecular Formula:
C16H26O5Molecular Weight:
298.37Precautions:
H302References & Citations:
[1]Xiao, S., et al., Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop, 2002. 82 (2) : p. 175-81.|[2]Wu, Z.P., et al., Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr Cancer Ther, 2009. 8 (1) : p. 88-92.|[3]Wu H, et al. Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway. Cell Death Dis. 2018 May 1;9 (5) :498. |[4]Wang JX, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol. 2007 Mar;150 (5) :652-61.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Natural ProductsClinical Information:
LaunchedIsoform:
PlasmodiumCAS Number:
[71963-77-4]
